NIU Disease Burden and the Case for New Therapeutics
Non-infectious uveitis accounts for an estimated 5–10% of blindness cases globally and disproportionately affects working-age adults—a burden that creates strong clinical and commercial pressure to move beyond systemic corticosteroids. NIU encompasses anterior, intermediate, posterior, and panuveitis; in many cases the etiology remains idiopathic, arising from autoimmune disorders, underlying systemic inflammatory disease, or trauma. The primary clinical goals identified across retrieved patents are control of inflammation, prevention of vision loss, and minimization of treatment-related complications—particularly those associated with long-term corticosteroid use.
At the molecular level, retrieved patent and literature data converge on several cytokine pathways as principal drivers of NIU pathology: the IL-6/IL-6R axis, IL-1β, IL-17A/IL-23, and TNF-α. A 2014 academic paper from Hospital Clinic de Barcelona documents elevated IFN-γ, IL-1β, IL-12p70, IL-17A, and TNF-α in Behçet’s disease-associated uveitis, providing independent biological rationale for the cytokine-targeting strategies observed in the patent landscape. According to WHO, inflammatory eye diseases remain a leading cause of preventable visual impairment in adults of working age, reinforcing the public health urgency behind this pipeline.
NIU is a heterogeneous group of intraocular inflammatory diseases—encompassing anterior, intermediate, posterior, and panuveitis—arising from autoimmune disorders, systemic inflammatory disease, or trauma. It is distinguished from infectious uveitis by the absence of a pathogenic microorganism, a distinction that Stanford University’s patent on vitreous and aqueous humor biomarker panels (PGLYRP1, ELANE, MMP9, S100A8, SPARCL1) is designed to help clinicians make at the point of care.
Non-infectious uveitis (NIU) accounts for an estimated 5–10% of blindness cases globally and disproportionately affects working-age adults. It encompasses anterior, intermediate, posterior, and panuveitis, with etiology ranging from autoimmune disorders to idiopathic causes.
Suprachoroidal Space Delivery: Clearside Biomedical’s Clinical-Stage Platform
Suprachoroidal space (SCS) delivery of triamcinolone acetonide—Clearside Biomedical’s CLS-TA—is the most clinically advanced local anti-inflammatory delivery platform in the NIU patent dataset, with Kaplan-Meier time-to-rescue data and best-corrected visual acuity (BCVA) change graphs cited in the company’s 2023 WO filing. The approach uses microneedle-based devices to inject drug non-surgically into the suprachoroidal space, targeting posterior ocular tissues including the retina and choroid, and avoids the systemic steroid exposure associated with oral prednisone.
Preclinical data referenced in Clearside’s patents compare SCS triamcinolone favorably against oral prednisone on cumulative inflammation scores and intraocular pressure. The 2023 WO filing references time-to-rescue probability data and BCVA change from baseline with intent-to-treat population analysis and statistical comparisons (ANOVA with fixed effects for treatment group), consistent with a controlled clinical trial dataset—the strongest clinical evidence in the retrieved results. Multiple filings remain active or pending in US, WO, AU, CA, IN, IL, HK, and CN jurisdictions.
An earlier modality from Allergan (now part of AbbVie)—bioerodible vitreous implants releasing glucocorticoids—predates the SCS platform but addresses the same unmet need for sustained intraocular drug exposure without systemic steroid exposure. The SCS approach represents a technological evolution: more targeted posterior segment delivery without surgical implantation. Clearside’s patents also describe optional co-administration with intravitreal VEGF modulators, establishing a potential dual-modality approach for macular edema with both vascular and inflammatory components.
“Suprachoroidal triamcinolone acetonide (CLS-TA) is the most clinically advanced local delivery platform in the NIU patent dataset, with Kaplan-Meier time-to-rescue data and BCVA change from baseline cited in a 2023 WO filing—the strongest clinical evidence in the retrieved results.”
Clearside Biomedical’s suprachoroidal space (SCS) triamcinolone acetonide (CLS-TA) program holds active or pending patent filings in at least eight jurisdictions (US, WO, AU, CA, IN, IL, HK, CN) and is the most clinically advanced local anti-inflammatory delivery platform in the non-infectious uveitis patent dataset, with controlled clinical trial data cited in a 2023 WO filing.
Analyse the full NIU patent landscape—assignee activity, legal status, and jurisdiction coverage—in PatSnap Eureka.
Explore NIU Patents in PatSnap Eureka →Cytokine-Targeted Biologics: IL-6R, IL-1β, and IL-17/23
The IL-6/IL-6R axis is the dominant commercial IP target for NIU biologics in this dataset. Regeneron Pharmaceuticals holds at least 14 patent filings across more than 10 jurisdictions (US, WO, EP, AU, CA, SG, IN, MX, TW) on sarilumab—an anti-IL-6R antibody—for NIU and uveitis-associated macular edema (UME), with active legal status filings in AU and US. Patient selection criteria in these patents are highly specific: vitreous haze (VH) ≥2 on the Miami 9-step scale, central retinal thickness (CRT) >300 μm, and NIU subtypes of intermediate, posterior, or panuveitis—specificity characteristic of clinical study protocols.
A complementary Roche/Hoffmann-La Roche filing introduces an in vitro aqueous humor IL-6 immunoassay for patient stratification—the first predictive biomarker strategy specifically linking aqueous IL-6 concentration to likelihood of response to intraocular IL-6 inhibition in this dataset. A Tomalin Biosciences filing (Taiwan, 2024) claims subcutaneous administration of an anti-IL-6 antibody or antibody fragment for NIU, indicating that the anti-IL-6 approach (distinct from anti-IL-6R) is also attracting new entrants.
IL-1β: A Late-Line Niche with Broad Jurisdictional Coverage
XOMA Technology Ltd. and XOMA (US) LLC represent the most prolific individual assignee for anti-IL-1β patents targeting uveitis in this dataset, with filings across at least eleven jurisdictions. The mechanism proposed is neutralization of IL-1β to reduce uveitis flares, increase inter-flare intervals, and address treatment-refractory disease that has failed steroids, DNA synthesis inhibitors (methotrexate, azathioprine, cyclophosphamide, chlorambucil), TNF inhibitors, IL-6 inhibitors, and IL-17 inhibitors. Most XOMA filings show inactive status in this dataset—which may represent a licensing or freedom-to-operate opportunity for companies pursuing IL-1β inhibition in refractory uveitis, subject to independent IP clearance analysis.
IL-17A/IL-23: Academic-Industry Co-Development and the Steroid-Taper Strategy
Schering Corporation (now part of Merck Sharp & Dohme Corp.) filed patents across at least eight jurisdictions on IL-17 and IL-23 antagonists for autoimmune ocular inflammatory disease, co-assigned with the U.S. National Institutes of Health (NIH) and individual inventor Rachel Caspi—underscoring academic-industry co-development. AceLyrin, Inc. filed a 2025 WO application specifically on an IL-17A inhibitor for NIU with a structured corticosteroid taper, with corticosteroid discontinuation targeted by week 15. This formalizes a steroid-sparing biologic approach with time-defined taper, a design pattern also referenced in XOMA anti-IL-1β patents.
Regeneron’s 2024 filings describe IPMK therapeutic agents and IDO2 agonists specifically for B27-negative anterior uveitis patients—the only genotype-guided intervention strategy in the retrieved dataset. Roche’s aqueous humor IL-6 immunoassay introduces a predictive biomarker for IL-6 antagonist response. Together, these represent the earliest evidence in this dataset of biomarker-stratified NIU treatment, with implications for clinical trial design and future reimbursement negotiations.
Regeneron Pharmaceuticals’ sarilumab (anti-IL-6R antibody) patents for non-infectious uveitis specify patient selection criteria of vitreous haze (VH) ≥2 on the Miami 9-step scale and central retinal thickness (CRT) >300 μm, covering intermediate, posterior, and panuveitis subtypes across at least 14 filings in 10+ jurisdictions.
Gene Therapy and Novel Formulations: Emerging Disruptors in the NIU Pipeline
Gene therapy via rAAV-mediated antibody delivery represents the most disruptive emerging modality in the NIU pipeline, though development remains at preclinical to early clinical stage based on retrieved patent data. RegenxBio Inc. has filed patents in CA, IL, and MX describing rAAV-mediated delivery of fully human post-translationally modified (HuPTM) monoclonal antibodies targeting TNF-α, IL-6, or IL-6R for NIU. A separate RegenxBio family covers vectorized TNFR-Fc fusion proteins. Pending legal status across multiple jurisdictions signals active pursuit of IP protection for this rAAV ocular antibody delivery platform.
The strategic logic is compelling: sustained intraocular expression of therapeutic proteins from a single or infrequent gene therapy dose could replace the repeat intravitreal injections required by conventional biologics. According to research published by Nature, sustained intraocular gene expression from AAV vectors has been demonstrated in multiple ocular indications, providing scientific precedent for this approach in NIU. The University of Bristol (2025 WO) filed on a combination of a TNF inhibitor and a CD3 inhibitor (with an inflammation-inducible promoter construct) for inflammatory eye disease—the only T-cell co-stimulation targeting strategy in this dataset.
Polymer Conjugates and Novel Small Molecules
Valitor, Inc. (2025) filed on multivalent TNFα inhibitor-hyaluronic acid polymer conjugates for intravitreal use in chronic NIU—a formulation innovation addressing the known limitations of off-label intravitreal biologics such as adalimumab. Aldeyra Therapeutics filed on a fused bicyclic amine compound (NS2) in combination with prednisolone acetate for anterior chamber cell reduction in uveitis, with clinical study parameters cited comparing NS2 alone versus NS2 + prednisolone acetate (Pred Forte). The U.S. Department of Health and Human Services holds an active patent on IL-24 polypeptides for uveitis, proposed to suppress Th17 effector cytokine production.
RegenxBio Inc. has filed patents in multiple jurisdictions describing rAAV-mediated delivery of fully human post-translationally modified (HuPTM) monoclonal antibodies targeting TNF-α, IL-6, or IL-6R for non-infectious uveitis, positioning gene therapy as a potential replacement for repeated intravitreal biologic injections. Development stage based on retrieved patent data is preclinical to early clinical.
Track RegenxBio, AceLyrin, and other emerging NIU pipeline entrants with real-time patent monitoring in PatSnap Eureka.
Monitor NIU Pipeline in PatSnap Eureka →IP Landscape and Strategic Implications for NIU Drug Developers
The NIU patent landscape is commercially dominated by a small number of well-resourced assignees whose filing strategies create meaningful freedom-to-operate challenges for new entrants. Regeneron’s multi-jurisdictional sarilumab patent family (active in AU, US) and Roche’s companion diagnostic approach together define a tightly IP-protected therapeutic and diagnostic niche around the IL-6/IL-6R axis. New entrants pursuing anti-IL-6R for NIU face significant freedom-to-operate challenges in key markets.
Several strategic implications emerge from the patent data. Anti-IL-1β IP (XOMA) appears largely inactive across most jurisdictions in this dataset, which may represent a licensing or freedom-to-operate opportunity for companies pursuing IL-1β inhibition in refractory uveitis—subject to independent IP clearance analysis beyond this dataset. Gene therapy (rAAV-delivered anti-TNF/anti-IL-6R) is an emerging but early-stage disruptive modality: RegenxBio’s filings signal that the next generation of NIU biologics may be administered as a single intraocular gene therapy dose rather than repeated injections. Investors evaluating ocular gene therapy should treat NIU as a secondary indication with growing IP activity.
The convergence of molecular patient stratification strategies from both Regeneron (IPMK/IDO2, B27-negative anterior uveitis) and Roche (aqueous humor IL-6 quantification) suggests that biomarker-guided NIU treatment is becoming an IP and clinical development priority. According to EMA guidance on companion diagnostics, co-development of a diagnostic and therapeutic from early clinical stages is increasingly expected for precision medicine indications—a regulatory dynamic that may accelerate adoption of the Roche aqueous humor IL-6 assay alongside anti-IL-6 therapy. Patent-driven activity dominates over literature-driven activity in this dataset, with academic contributions limited to cytokine profiling in Behçet’s uveitis (Hospital Clinic de Barcelona) and intravitreal bevacizumab for uveitic macular edema (King Khaled Eye Specialist Hospital, Riyadh).
“Anti-IL-1β IP (XOMA) appears largely inactive across most jurisdictions in this dataset—which may represent a licensing or freedom-to-operate opportunity for companies pursuing IL-1β inhibition in refractory uveitis, subject to independent IP clearance analysis.”